AGBT 2017: Knowledge-enabled Workflow for Virtual Molecular Tumor Board
An overview of GenomOncology's Knowledge-Enabled workflow solution for virtual Molecular Tumor Boards. GenomOncology's Precision Oncology Platform (POP) streamlines the work of the multidisciplinary tumor board, reducing the preparation time for a case review.
September 14, 2017
Adoption of molecular tumor profiling via next generation sequencing (NGS) is on the rise due to decreased cost and improved clinical actionability. However, due to high volume of information and guideline complexity, difficulty in accurate interpretation of molecular testing results persists. Virtual multidisciplinary molecular tumor conferences (“molecular tumor boards”) have been proposed as a solution. Molecular tumor boards have been shown to improve patient outcome in a variety of cancer types, and have thus become a standard of care for oncology treatment planning. A knowledge enabled software application can address many of the complexities and inefficiencies facing molecular tumor board programs.
The GenomOncology Precision Oncology Platform (POP) streamlines the work of the multidisciplinary tumor board, reducing preparation time for case review while providing a workflow for the structured analysis of NGS and other test results. High-level features include...
Real-time and asynchronous team-based communication and workflow
Ability to aggregate patient demographic info with molecular testing results
Clinical decision support provided by My Cancer Genome, FDA, NCCN, and ASCO guidelines, including EU guidelines
Biomarker-based matching to clinical trials curated from clinicaltrials.gov
Workflow and tools for the creation of a recommendation report
This application utilizes a combination of extensive molecular information within the knowledge management system (KMS), and a proprietary contextual Match algorithm. The KMS enables teams to interact with existing data sources (FDA, NCCN, ASCO, MCG) in a programmatic manner to enable therapeutic and prognostic recommendations. In addition to professional guidelines, the KMS offers access to Vanderbilt’s My Cancer Genome, a leading knowledge resource matching tumor mutations to therapies. Decision support is powered by the contextual Match algorithm, and a full disease ontology that recommends therapies, prognoses and trials for patients based on molecular and clinical information. By utilizing this solution, healthcare professionals and institutions can more accurately guide and manage patient treatment.